RT Journal Article
SR Electronic
T1 Use of rapid molecular tuberculosis diagnostics across Brazil’s incarcerated population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.30.21266839
DO 10.1101/2021.11.30.21266839
A1 Elinor B. Fajer
A1 Fernanda Dockhorn Costa
A1 Daniele Maria Pelissari
A1 Fredi Alexander Diaz Quijano
A1 Artemir Coelho de Brito
A1 Eunice Atsuko Totumi Cunha
A1 Julio Croda
A1 Jason R. Andrews
A1 Katharine S. Walter
YR 2021
UL http://medrxiv.org/content/early/2021/12/02/2021.11.30.21266839.abstract
AB Background Incarcerated individuals in Brazil are at high-risk of tuberculosis (TB), but their access to World Health Organization recommended diagnostics is poorly understood.Methods We conducted a retrospective cross-sectional study of newly diagnosed TB cases in Brazil’s notifiable disease registry, which includes information on diagnostic tests performed, from January 2015 through December 2018. We quantified reported use of TB diagnostics across incarcerated and non-incarcerated populations and tested for municipality-level factors associated with diagnostic usage among the incarcerated population with generalized linear regression.Results Between 2015 and 2018, 258,014 individuals were newly diagnosed with TB, including 27,400 (10.6%) incarcerated individuals. Among these, 27.5% had an Xpert MTB/RIF test reported; 71.5% had sputum smear; 34.1% had culture; 70.9% had chest radiography. Xpert MTB/RIF use was greater among incarcerated than non-incarcerated individuals (36.2% vs 26.5%, p<0.001). However, we found spatial heterogeneity in state-level use of both Xpert MTB/RIF (range: 4.7-72.4% cases diagnosed) and chest radiography (range: 11.7-88.4%) in prisons. We identified seven municipalities with large incarcerated populations (>5000) with rates of Xpert MTB/RIF usage below the national average in incarcerated individuals.Conclusion Prioritizing expansion of rapid molecular diagnostics in prisons, particularly in regions with limited current usage of molecular diagnostics, will be an essential component of TB control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: National Institutes of Health grant R01 AI130058 (JRA) and R01 AI149620 (JRA and JC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at Stanford University (Protocol #50466).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors